Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.81 |
| ▸ | HRH2 | P25021 | 1/20 | 0.52 |
| ▸ | HRH1 | P35367 | 1/20 | 0.52 |
| ▸ | PARP10 | Q53GL7 | 6/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | PARP15 | Q460N3 | 4/20 | 0.49 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.49 |
| ▸ | ESRRB | O95718 | 2/20 | 0.47 |
| ▸ | ESR1 | P03372 | 2/20 | 0.47 |
| ▸ | ESRRG | P62508 | 2/20 | 0.47 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4292974 | 1.00 | HRH3 (0.81) | HRH3HRH2HRH1PARP10MAOB | |
| Hydrochloric Acid SCHEMBL3828271 | 0.99 | HRH3 (0.79) | HRH3HRH2HRH1PARP10MAOB | |
| Oxalic Acid SCHEMBL3824009 | 0.96 | HRH3 (0.75) | HRH3HRH2HRH1PARP10MAOB | |
| SCHEMBL3828820 | 0.96 | HRH3 (0.74) | HRH3HRH2HRH1PARP10MAOB | |
| SCHEMBL3827146 | 0.93 | HRH3 (0.70) | HRH3HRH2HRH1PARP10PARP15 | |
| SCHEMBL1977578 | 0.92 | HRH3 (0.90) | HRH3HRH2HRH1PARP10MAOB | |
| Hydrochloric Acid SCHEMBL1979057 | 0.90 | HRH3 (0.88) | HRH3HRH2HRH1PARP10MAOB | |
| SCHEMBL14152811 | 0.89 | HRH3 (1.00) | HRH3HRH2HRH1PARP10MAOB | |
| SCHEMBL14158615 | 0.89 | HRH3 (1.00) | HRH3HRH2HRH1PARP10MAOB | |
| SCHEMBL14152810 | 0.89 | HRH3 (1.00) | HRH3HRH2HRH1PARP10MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906547-B2 | Azabicylic compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2011-03-15 | — | — | US | claimed |
| US-20090312389-A1 | Azabicylic compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2009-12-17 | — | — | US | claimed |
| EP-2133333-A1 | New azabicyclic derivatives, method of preparing same and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2009-12-16 | — | — | EP | claimed |
| US-7906547-B2 | Azabicylic compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2011-03-15 | — | — | US | disclosed |
| US-20090312389-A1 | Azabicylic compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2009-12-17 | — | — | US | disclosed |
| EP-2133333-A1 | New azabicyclic derivatives, method of preparing same and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2009-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312389-A1 | Azabicylic compounds, a process for their preparation and pharmaceutical compositions containing them | CHAT, MAOB, ALKBH2 | HRH3 2086/4885HRH2 3648/4885HRH1 2733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.